- DARPin Radioligand Therapy platform progressing well. Disclosure of the tumor-associated protein Delta-like ligand 3 (DLL3) as the first target. Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.
- Year-end 2022 unaudited cash and short-term deposits
~CHF249m . Company continues to maintain expected cash runway into 2026.* Molecular Partners and Novartis signed a non-binding letter of intent to negotiate a Research Framework Agreement with a primary focus on emerging infectious global health threats. The Parties agree that the Definitive Agreement if concluded, shall contain provisions covering research plans, governance, development and commercialization, intellectual property, and the potential to prioritize future pandemic projects
The company expects milestones in 2023 to include:
- Q1 2023: The recruitment of the first patient in the company’s phase 1 study of MP0533 (CD33 X CD123 X CD70 X CD3), a novel tri-specific t-cell engager for the treatment of AML and High Risk MDS
- 1H 2023: Complete recruitment in the dose escalation of the Phase 1 trial of the company’s MP0317 (FAP X CD40) program for the treatment of solid tumors
- H1 2023: Scientific presentations of DARPin radioligand therapies and their potential differentiation as tumor targeting moiety
- Formal selection of DLL3 DARPin RLT clinical candidate
- Q4 2023: A first data readout from the Phase 1 study of MP0533
Ensovibep Update:
Molecular Partners was informed by its partner Novartis that it has submitted a request to withdraw the Emergency Use Authorization (EUA) application from theU.S. Food and Drug Administration (FDA) for ensovibep, a DARPin therapeutic candidate to treat COVID-19.- As previously disclosed, ensovibep is not presently in clinical development.
*Unaudited financials. YE audited results will be available
About
For further details, please contact:
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Zurich-Schlieren,
antonio.ligi@molecularpartners.com
Tel: +41 79 723 36 81
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners’ product candidates, the selection and development of future antiviral or other programs, and Molecular Partners’ expected expenses and cash utilization for 2022 and its expectation that its current cash resources will be sufficient to fund its operations and capital expenditure requirements into 2026. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, “would” and similar expressions, and are based on Molecular Partners AG’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the potential impact of the COVID-19 pandemic on Molecular Partners’ preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners’ Annual Report on Form 20-F for the fiscal year ended
![](https://ml.globenewswire.com/media/MTgwOGMyMGEtNmMzMi00MWM2LThmMjYtODliYTI4ZjNjNWIxLTEyMTY1NDg=/tiny/Molecular-Partners.png)
2023 GlobeNewswire, Inc., source